Scholarlink

<p>Recellularization of acellular lung scaffolds is a promising technique for the generation of bioengineered lungs. However, at the present time, pre-clinical evaluation of bioengineered lungs shows graft failure likely due to thrombus formation and bleeding from bronchi. This is believed to be due to the impairment of barrier function, incomplete vascular endothelial cell coverage, and limited endothelial cell function. Therefore, efficient recellularization of the vasculature region of the lung scaffold with functional endothelial cells is an important goal. Coating of decellularized tissues, prior to recellularization has shown improved vascular endothelial cell coverage and endothelial cell function. Here, we report the first demonstration of preconditioning decellularized lung vasculature with an anti‑CD31 antibody to enhance re-endothelialization and vascular function in bioengineered lungs. Presence of the anti-CD31 antibody (Ab) coating resulted in enhanced cell adhesion, viability, proliferation and expression of key endothelial cell genes including Claudin-1 (CLDN) and Endothelial Nitric Oxide Synthase (eNOS). Re-endothelialized scaffolds in the anti-CD31 Ab coated group had morphological reconstitution of the pulmonary vasculature and a higher percentage of endothelialized blood vessels. Markedly greater fractions of intravascular Dextran in the anti-CD31 Ab coated group (20.7 ± 2.5% vesus 51.7 ± 2.5%, <i>p</i> = 0.0001) demonstrated reduced vascular endothelium leakage. Importantly, scaffolds in the anti-CD31 Ab coated group showed reduced platelet aggregation, measured via staining and quantification for integrin αIIb, when perfused with whole-blood ex vivo (17.7 ± 3.8% vs. 6.7 ± 1.5%, <i>p</i> = 0.04); and in vivo following a 30&#xa0;min-left orthotopic left lung transplant in the mouse (14.7 ± 2.5% vs. 4.3 ± 1.5% in the anti-CD31 group (<i>p</i> = 0.004); suggesting reduced thrombus formation. Taken together, our results frame scaffold preconditioning with anti-CD31 Ab as a viable approach towards the generation of vascularized bioengineered lung constructs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anti-CD31 antibody preconditioning for enhancement of endothelial cell capture and vascularization: a novel strategy for bioengineering lung scaffolds

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Satoshi Kamata,
  • Arash Zargar,
  • Daisuke Taniguchi,
  • Yamato Suzuki,
  • Abbie Lo,
  • Shiyuan Bian,
  • Ethan Chen,
  • Samantha Ligi,
  • Shaf Keshavjee,
  • Yoshinori Okada,
  • Siba Haykal,
  • Aimy Bazylak,
  • Thomas K. Waddell,
  • Golnaz Karoubi

摘要

Recellularization of acellular lung scaffolds is a promising technique for the generation of bioengineered lungs. However, at the present time, pre-clinical evaluation of bioengineered lungs shows graft failure likely due to thrombus formation and bleeding from bronchi. This is believed to be due to the impairment of barrier function, incomplete vascular endothelial cell coverage, and limited endothelial cell function. Therefore, efficient recellularization of the vasculature region of the lung scaffold with functional endothelial cells is an important goal. Coating of decellularized tissues, prior to recellularization has shown improved vascular endothelial cell coverage and endothelial cell function. Here, we report the first demonstration of preconditioning decellularized lung vasculature with an anti‑CD31 antibody to enhance re-endothelialization and vascular function in bioengineered lungs. Presence of the anti-CD31 antibody (Ab) coating resulted in enhanced cell adhesion, viability, proliferation and expression of key endothelial cell genes including Claudin-1 (CLDN) and Endothelial Nitric Oxide Synthase (eNOS). Re-endothelialized scaffolds in the anti-CD31 Ab coated group had morphological reconstitution of the pulmonary vasculature and a higher percentage of endothelialized blood vessels. Markedly greater fractions of intravascular Dextran in the anti-CD31 Ab coated group (20.7 ± 2.5% vesus 51.7 ± 2.5%, p = 0.0001) demonstrated reduced vascular endothelium leakage. Importantly, scaffolds in the anti-CD31 Ab coated group showed reduced platelet aggregation, measured via staining and quantification for integrin αIIb, when perfused with whole-blood ex vivo (17.7 ± 3.8% vs. 6.7 ± 1.5%, p = 0.04); and in vivo following a 30 min-left orthotopic left lung transplant in the mouse (14.7 ± 2.5% vs. 4.3 ± 1.5% in the anti-CD31 group (p = 0.004); suggesting reduced thrombus formation. Taken together, our results frame scaffold preconditioning with anti-CD31 Ab as a viable approach towards the generation of vascularized bioengineered lung constructs.